Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections (DRESS)
A Randomized, Observer-blinded, Active-controlled, Phase Illb Study to Compare IV / Oral Delafloxacin Fixed-dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections
Sponsor: Menarini Group
Terminated
COVID-19 seriously affected the study execution as required by the protocol
Other terminated trials from Menarini Group
- Acute Myeloid Leukemia, in Relapse · Phase PHASE1 · Apr 2021
- Metastatic Solid Tumors · Phase PHASE1 · Jan 2020
- Tumor Lysis Syndrome · Phase PHASE1/PHASE2 · Jul 2018
- Irritable Bowel Syndrome With Diarrhea · Phase PHASE3 · Nov 2015
- Ovarian Cancer · Phase PHASE2/PHASE3 · Jun 2011
More terminations from Menarini Group
Other Surgical Site Infection trials with similar outcome
This PHASE3 trial investigates Surgical Site Infection and is currently terminated or withdrawn. Menarini Group leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Nov 2021 — Mar 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Nov 2021 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Apr 2020 — Dec 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Menarini Group
For direct contact, visit the study record on ClinicalTrials.gov .